Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety study of NNC6022-0004 in healthy participants and participants with obesity
NL-OMON61280Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of NNC6022-0004 in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Primary endpoint(s). Started Jul 2026; status: recruiting.
02
Drugs
NNC6022-0004
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON61280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61280.